CCL2 and insulin-resistant diabetes mellitus: MCP-1is among the most studied chemokines and is a therapeutic target in the treatment of various diseases, including multiple sclerosis, rheumatoid arthritis, atherosclerosis, allergic conditions, and insulin-resistant diabetes (Deshmane et al. 2009; Yadav et al. 2010). Animal models (genetically deficient mice, antibody- or inhibitor-mediated neutralization in mice) that neutralised overexpression of MCP-1 in these disease states showed substantially improved recovery rates (Deshmane et al. 2009; Yadav et al. 2010).